APOC3 and hypertriglyceridemia: As such, novel molecules targeting apoCIII currently under investigation in preclinical and clinical trials are promising therapeutic candidates for the treatment of moderate hypertriglyceridemia to prevent ASCVD (54) and may be applicable to patients with SZ given their elevated TG, TRL concentration, and non-HDL-apoCIII levels.